The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
YC-1: A Potential Anticancer Drug Targeting Hypoxia-Inducible Factor 1
Abstract
BACKGROUND: Hypoxia-inducible factor 1 alpha (HIF-1alpha), a component of HIF-1, is expressed in human tumors and renders cells able to survive and grow under hypoxic (low-oxygen) conditions. YC-1, 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole, an agent developed for circulatory disorders that inhibits platelet aggregation and vascular contraction, inhibits HIF-1 activity in vitro. We tested whether YC-1 inhibits HIF-1 and tumor growth in vivo. METHODS: Hep3B hepatoma, NCI-H87 stomach carcinoma, Caki-1 renal carcinoma, SiHa cervical carcinoma, and SK-N-MC neuroblastoma cells were grown as xenografts in immunodeficient mice (69 mice total). After the tumors were 100-150 mm(3), mice received daily intraperitoneal injections of vehicle or YC-1 (30 microg/g) for 2 weeks. HIF-1 alpha protein levels and vascularity in tumors were assessed by immunohistochemistry, and the expression of HIF-1-inducible genes (vascular endothelial growth factor, aldolase, and enolase) was assessed by reverse transcription-polymerase chain reaction. All statistical tests were two-sided. RESULTS: Compared with tumors from vehicle-treated mice, tumors from YC-1-treated mice were statistically significantly smaller (P<.01 for all comparisons), expressed lower levels of HIF-1 alpha (P<.01 for all comparisons), were less vascularized (P<.01 for all comparisons), and expressed lower levels of HIF-1-inducible genes, regardless of tumor type. CONCLUSIONS: The inhibition of HIF-1 alpha activity in tumors from YC-1-treated mice is associated with blocked angiogenesis and an inhibition of tumor growth. YC-1 has the potential to become the first antiangiogenic anticancer agent to target HIF-1 alpha.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
Jaakkola, P., Mole, D. R., Tian, Y.-M., Wilson, M. I., Gielbert, J., Gaskell, S. J., Kriegsheim, A. V., Hebestreit, H. F., Mukherji, M., Schofield, C. J., et al. (2001) · Science · doi:10.1126/science.1059796 · Cited by 5,535
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180
HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O 2 Sensing
Ivan, M., Kondo, K., Yang, H., Kim, W., Valiando, J., Ohh, M., Salic, A., Asara, J. M., Lane, W. S., & Kaelin Jr., W. G. (2001) · Science · doi:10.1126/science.1059817 · Cited by 4,735
Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1
Forsythe, J. A., Jiang, B.-H., Iyer, N. V., Agani, F., Leung, S. W., Koos, R. D., & Semenza, G. L. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.9.4604 · Cited by 3,981
Tumor Hypoxia: Definitions and Current Clinical, Biologic, and Molecular Aspects
Hockel, M., & Vaupel, P. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.4.266 · Cited by 2,662
Mechanism of Action and In Vivo Role of Platelet-Derived Growth Factor
Heldin, C.-H., & Westermark, B. (1999) · Physiological Reviews · doi:10.1152/physrev.1999.79.4.1283 · Cited by 2,496
International Journal of Oncology
(2026) · International Journal of Oncology · doi:10.3892/ijo · Cited by 2,331
(1999) · PubMed · Cited by 2,204
Huang, L. E., Gu, J., Schau, M., & Bunn, H. F. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.14.7987 · Cited by 2,113
Purification and Characterization of Hypoxia-inducible Factor 1
Wang, G. L., & Semenza, G. L. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.3.1230 · Cited by 2,073
Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1.
Semenza, G. L., Roth, P. H., Fang, H. M., & Wang, G. L. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)31580-6 · Cited by 1,897
Maxwell, P. H., Dachs, G. U., Gleadle, J. M., Nicholls, L. G., Harris, A. L., Stratford, I. J., Hankinson, O., Pugh, C. W., & Ratcliffe, P. J. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.15.8104 · Cited by 1,084
HIF-1 and tumor progression: pathophysiology and therapeutics
Semenza, G. L. (2002) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(02)02317-1 · Cited by 1,060
Masson, N., Willam, C., Maxwell, P. H., Pugh, C. W., & Ratcliffe, P. J. (2001) · The EMBO Journal · doi:10.1093/emboj/20.18.5197 · Cited by 1,014
Brown, J. M. (1999) · PubMed · Cited by 698
(2000) · PubMed · Cited by 614
YC-1, a novel activator of platelet guanylate cyclase
Ko, F., Wu, C., Kuo, S., Lee, F., & Teng, C. (1994) · Blood · doi:10.1182/blood.v84.12.4226.bloodjournal84124226 · Cited by 402
Hypoxia modulated gene expression: angiogenesis, metastasis and therapeutic exploitation
Dachs, G. U., & Tozer, G. M. (2000) · European Journal of Cancer · doi:10.1016/s0959-8049(00)00159-3 · Cited by 272
Kim, C.-H., Cho, Y.-S., Chun, Y.-S., Park, J.-W., & Kim, M.-S. (2002) · Circulation Research · doi:10.1161/hh0202.104923 · Cited by 228
Self-citationGalle, J., Zabel, U., Hübner, U., Hatzelmann, A., Wagner, B., Wanner, C., & Schmidt, H. H. H. W. (1999) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0702495 · Cited by 173
YC-1 Potentiates Nitric Oxide- and Carbon Monoxide-Induced Cyclic GMP Effects in Human Platelets
Friebe, A., Müllershausen, F., Smolenski, A., Walter, U., Schultz, G., & Koesling, D. (1998) · Molecular Pharmacology · doi:10.1124/mol.54.6.962 · Cited by 167
Chun, Y.-S., Yeo, E.-J., Choi, E., Teng, C.-M., Bae, J.-M., Kim, M.-S., & Park, J.-W. (2001) · Biochemical Pharmacology · doi:10.1016/s0006-2952(01)00564-0 · Cited by 151
Self-citationA new HIF-1 alpha variant induced by zinc ion suppresses HIF-1-mediated hypoxic responses
Chun, Y., Choi, E., Yeo, E.-J., Lee, J.-H., Kim, M.-S., & Park, J. (2001) · Journal of Cell Science · doi:10.1242/jcs.114.22.4051 · Cited by 109
Self-citationA dominant-negative isoform lacking exons 11 and 12 of the human hypoxia-inducible factor-1α gene
Chun, Y., Choi, E., Kim, T., Kim, M.-S., & Park, J. (2002) · Biochemical Journal · doi:10.1042/0264-6021:3620071 · Cited by 96
Self-citationHypoxia-inducible factor: Achilles' heel of antiangiogenic cancer therapy (Review)
Blagosklonny, M. V. (2001) · International Journal of Oncology · doi:10.3892/ijo.19.2.257 · Cited by 92
Teng, C., Wu, C., Ko, F., Lee, F., & Kuo, S. (1997) · European Journal of Pharmacology · doi:10.1016/s0014-2999(96)00911-9 · Cited by 85
Rothermund, L., Friebe, A., Paul, M., et al. (2000) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0703320 · Cited by 55
Angiogenesis, a target for tumor therapy
Griffioen, A. W., Barendsz-Janson, A. F., Mayo, K. H., & Hillen, H. F. P. (1998) · Journal of Laboratory and Clinical Medicine · doi:10.1016/s0022-2143(98)90106-8 · Cited by 26
Research works printed but not linked: 5
- Brown, 1999, Cancer Research, 59, 5863
- Zhong, 1999, Cancer Research, 59, 5830
- Birner, 2000, Cancer Research, 60, 4693
- Yajima, 2002, International journal of cancer. Journal international du cancer, 99, 573, 10.1002/ijc.10395 · doi:10.1002/ijc.10395
- Klein, 1979, Experimental cell biology, 47, 430
Cited by
Targeting HIF-1 for cancer therapy
Semenza, G. L. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1187 · Cited by 6,717
Exploiting tumour hypoxia in cancer treatment
Brown, J. M., & Wilson, W. R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1367 · Cited by 2,828
Hypoxia-inducible factor (HIF-1)α: its protein stability and biological functions
Lee, J.-W., Bae, S.-H., Jeong, J.-W., Kim, S.-H., & Kim, K.-W. (2004) · Experimental & Molecular Medicine · doi:10.1038/emm.2004.1 · Cited by 1,117
Self-citationRadiation activates HIF-1 to regulate vascular radiosensitivity in tumors
Moeller, B. J., Cao, Y., Li, C. Y., & Dewhirst, M. W. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00115-1 · Cited by 996
Hydroxylation of HIF-1: Oxygen Sensing at the Molecular Level
Semenza, G. L. (2004) · Physiology · doi:10.1152/physiol.00001.2004 · Cited by 905
Metadata
- Authors
- Yeo, E.-J., Chun, Y.-S., Cho, Y.-S., Kim, J., Lee, J.-C., Kim, M.-S., & Park, J.-W.
- Venue
- JNCI Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 2003-04-02
- Volume
- 95
- Issue
- 7
- Pages
- 516-525
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- OpenAlex
- W2146270900
- Cited by
- 476
- References
- 29
- FWCI
- 9.59
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.